MaxCyte IPO Presentation Deck

Seamless Scale-up from 100ul to 1,000ul Transfection Volume with No Loss of Editing Efficiency in Primary T Cells A study conducted at a leading US academic institution evaluated gene-editing efficiency in primary CD45+/CD3- T cells using MaxCyte's ExPERT Platform at 100uL and 1,000uL volumes. After 5 days following electroporation, the data showed ~95% editing with no change in efficiency despite a 10x difference in scale. Feature Cassette type Max volume Min volume # EP/cassette Low cell # High cell # July 2021 OC-100 M 100UL 50uL 1 500,000 20 million R-1000 U 1mL 500uL 1 5 million 200 million % CD45+/CD3- 100 80 60 40 20 0 CONFIDENTIAL High editing efficiency across PAS (10x difference in scale) and lasting 79% 80% 48 Hours ■No EP ■OC100 R1000 95% Day 5 96% M MaxCyte

View entire presentation